



Calithera Biosciences to Present at the BIO CEO & Investor and Leerink Global Healthcare Conferences in February

February 3, 2015

SOUTH SAN FRANCISCO, Calif., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation in two investor conferences during the month of February.

The 17th Annual BIO CEO & Investor Conference

On Monday, February 9, 2015, Susan M. Molineaux, Ph.D., Founder, President and Chief Executive, will present a corporate update at 5:00 pm EST. The BIO CEO and Investor meeting is being held at the Waldorf Astoria in New York City.

Leerink Global Healthcare Conference

On Wednesday, February 11, 2015, Dr. Molineaux will participate in a fireside chat to discuss recent corporate developments at the Leerink Global Healthcare Conference being held in New York City at 3:55 p.m. EST.

These presentations will be webcast live and available for replay for up to 30 days at www.calithera.com in the Investor Relations section.

About Calithera

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera's lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. Calithera is headquartered in South San Francisco. For more information about Calithera, please visit www.calithera.com.

Forward Looking Statements

This news release contains forward-looking statements by Calithera that involve risks and uncertainties. Actual results may differ from Calithera's expectations and important factors that could cause actual results to differ materially. Calithera's product candidates may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's Quarterly Report on Form 10-Q for the period ended September 30, 2014 and other periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

CONTACT: Jennifer McNealey

ir@Calithera.com

650-870-1071

[Calithera Biosciences](http://www.calithera.com)

Calithera Biosciences Inc